| Title: | Hepatic SREBP signaling requires SPRING to govern systemic lipid metabolism in mice and humans |
| Journal: | Nature Communications |
| Published: | 25 Aug 2023 |
| Pubmed: | https://pubmed.ncbi.nlm.nih.gov/37626055/ |
| DOI: | https://doi.org/10.1038/s41467-023-40943-1 |
| URL: | https://www.nature.com/articles/s41467-023-40943-1.pdf |
Publication 7682
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
Abstract
The sterol regulatory element binding proteins (SREBPs) are transcription factors that govern cholesterol and fatty acid metabolism. We recently identified SPRING as a post-transcriptional regulator of SREBP activation. Constitutive or inducible global ablation of Spring in mice is not tolerated, and we therefore develop liver-specific Spring knockout mice (LKO). Transcriptomics and proteomics analysis reveal attenuated SREBP signaling in livers and hepatocytes of LKO mice. Total plasma cholesterol is reduced in male and female LKO mice in both the low-density lipoprotein and high-density lipoprotein fractions, while triglycerides are unaffected. Loss of Spring decreases hepatic cholesterol and triglyceride content due to diminished biosynthesis, which coincides with reduced very-low-density lipoprotein secretion. Accordingly, LKO mice are protected from fructose diet-induced hepatosteatosis. In humans, we find common genetic SPRING variants that associate with circulating high-density lipoprotein cholesterol and ApoA1 levels. This study positions SPRING as a core component of hepatic SREBP signaling and systemic lipid metabolism in mice and humans.</p>
16 Authors
- Sebastian Hendrix
- Jenina Kingma
- Roelof Ottenhoff
- Masoud Valiloo
- Monika Svecla
- Lobke F. Zijlstra
- Vinay Sachdev
- Kristina Kovac
- Johannes H. M. Levels
- Aldo Jongejan
- Jan F. de Boer
- Folkert Kuipers
- Antoine Rimbert
- Giuseppe D. Norata
- Anke Loregger
- Noam Zelcer
4 Applications
| Application ID | Title |
|---|---|
| 26041 | Large-Scale Sequencing in the UK Biobank to Facilitate Gene Discovery, Genome Sciences, and Precision Medicine |
| 31063 | Methodological extensions to estimate genetic heritability and shared risk factors for phenotypes of the UK Biobank |
| 48511 | Reprocessing and joint calling of UKBB exomes with gnomAD, genotype-phenotype analysis and open release via dedicated portals |
| 49823 | Genetic predisposition to cardiovascular and metabolic diseases |
Enabling scientific discoveries that improve human health